AstraZeneca

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

The European Medicines Agency (EMA) has granted AstraZeneca's (AZ) COVID-19 vaccine, Vaxzevria – ChAdOx1-S [Recombinant] – full Marketing Authorisation (MA) in the EU.

GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment

The vaccine was well-tolerated and no safety concerns were observed. For the prevention of RSV disease in newborns and children, AstraZeneca and Sanofi’s Beyfortus (nirsevimab) was recommended for conditional

Alexion's Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Alexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) compared to an

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival. AstraZeneca (AZ) has announced positive high-level results from two individual advanced breast cancer trials evaluating both its next-generation oral selective

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

AstraZeneca’s Imjudo (tremelimumab) – an anti-CTLA4 antibody – in combination with Imfinzi (durvalumab) – an anti-PD-L1 antibody – has been approved by the US Food and Drug Administration (FDA) for the

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]